1
|
The Lancet Haematology. Black lives matter in haematology. Lancet Haematol 2020; 7:e499. [PMID: 32589968 DOI: 10.1016/s2352-3026(20)30182-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
|
2
|
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica 2016; 101:115-208. [PMID: 26819058 PMCID: PMC4938336 DOI: 10.3324/haematol.2015.136739] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 01/27/2016] [Indexed: 01/28/2023] Open
Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap.The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders.The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
Collapse
Affiliation(s)
| | | | - Anneke Brand
- Leids Universitair Medisch Centrum, Leiden, the Netherlands
| | | | | | | | | | | | - Willem Fibbe
- Leids Universitair Medisch Centrum, Leiden, the Netherlands
| | - Tony Green
- Cambridge Institute for Medical Research, United Kingdom
| | - Fleur de Haas
- European Hematology Association, The Hague, the Netherlands
| | | | | | | | - Gilles Salles
- Hospices Civils de Lyon/Université de Lyon, Pierre-Bénite, France
| | | |
Collapse
|
3
|
Scharf RE. [The ambivalence of progress - do we need a less-is-more strategy?**. **Extract from the programmtic opening speech delivered at the 59th Annual GTH Congress 2015]. Hamostaseologie 2015; 35:376-377. [PMID: 26536623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
Economizing health care systems has led to industrialized hospitals. The consequences and side effects are substantial and rather promote costs explosion due to the dictated increase in cases and efficiency. Hence, position sensing and change in direction are required. Effective ways to find out of the current crisis are discussed.
Collapse
|
4
|
Kitamura K. [Technical evaluation of medical practice--conversion from things to skill and art. Topics: VI. Issues on fee for medical services in 20 internal medicine fields: 9. Hematology area]. Nihon Naika Gakkai Zasshi 2014; 103:3039-41. [PMID: 25812328 DOI: 10.2169/naika.103.3039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Kim JW, Kang DM. Compensation for work-related hematologic, liver, and infectious diseases. J Korean Med Sci 2014; 29 Suppl:S66-71. [PMID: 25006327 PMCID: PMC4085178 DOI: 10.3346/jkms.2014.29.s.s66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Accepted: 05/02/2014] [Indexed: 11/20/2022] Open
Abstract
Occupational diseases may be defined only medically or scientifically, and even then, their definition is not simple. However, compensable occupational diseases involve the additional layer of legal systems and social welfare policies as well. Their multifaceted nature makes determining the work-relatedness of these diseases more complex. Korea has established standards for the recognition of occupational diseases in Schedule 5 of the Enforcement Decree of the Labor Standards Act, and specific criteria for the recognition of occupational diseases are listed in Schedule 3 of the Enforcement Decree of the Industrial Accident Compensation Insurance Act. The new list of compensable occupational diseases comprises 13 articles as an open-ended system. The newly added articles pertain to lymphohematopoietic (Article 5) and infectious diseases (Article 9), as well as diseases of other target organs. Furthermore, the article on liver diseases (Article 8) has been partially revised. The new act has been changed to clarify the meaning as it has been presented in recent research. It is necessary to achieve agreement among concerned parties, including experts from the legal, medical, and social domains to resolve the issues of work-relatedness, causation, notion of aggravation, and so on for preparing a list and a process that are more reasonable.
Collapse
Affiliation(s)
- Jung-Won Kim
- Department of Occupational and Environmental Medicine, Kosin University College of Medicine, Busan, Korea
| | - Dong-Mug Kang
- Department of Preventive and Occupational Medicine, School of Medicine, Pusan National University, Yangsan, Korea
| |
Collapse
|
6
|
Gluckman E, Ruggeri A, Rocha V, Baudoux E, Boo M, Kurtzberg J, Welte K, Navarrete C, van Walraven SM. Family-directed umbilical cord blood banking. Haematologica 2011; 96:1700-7. [PMID: 21750089 PMCID: PMC3208689 DOI: 10.3324/haematol.2011.047050] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2011] [Revised: 06/16/2011] [Accepted: 06/30/2011] [Indexed: 01/21/2023] Open
Abstract
Umbilical cord blood transplantation from HLA-identical siblings provides good results in children. These results support targeted efforts to bank family cord blood units that can be used for a sibling diagnosed with a disease which can be cured by allogeneic hematopoietic stem cell transplantation or for research that investigates the use of allogeneic or autologous cord blood cells. Over 500 patients transplanted with related cord blood units have been reported to the Eurocord registry with a 4-year overall survival of 91% for patients with non-malignant diseases and 56% for patients with malignant diseases. Main hematologic indications in children are leukemia, hemoglobinopathies or inherited hematologic, immunological or metabolic disorders. However, family-directed cord blood banking is not widely promoted; many cord blood units used in sibling transplantation have been obtained from private banks that do not meet the necessary criteria required to store these units. Marketing by private banks who predominantly store autologous cord blood units has created public confusion. There are very few current validated indications for autologous storage but some new indications might appear in the future. Little effort is devoted to provide unbiased information and to educate the public as to the distinction between the different types of banking, economic models and standards involved in such programs. In order to provide a better service for families in need, directed-family cord blood banking activities should be encouraged and closely monitored with common standards, and better information on current and future indications should be made available.
Collapse
Affiliation(s)
- Eliane Gluckman
- Eurocord, Hospital Saint Louis, University Paris VII, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Tan SS, Van Gils CWM, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA. The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health 2010; 13:712-719. [PMID: 20561330 DOI: 10.1111/j.1524-4733.2010.00740.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
OBJECTIVES Many economic evaluations are conducted in the fields of oncology and hematology, partially owing to the introduction of new expensive drugs in this field. Even though inpatient days, outpatient visits, and daycare treatments are frequently the main drivers of total treatment costs, their unit costs often lack generalizability. Therefore, we aimed to determine the unit costs of inpatient hospital days, outpatient visits, and daycare treatments specifically for oncological and hematological diseases in The Netherlands from the hospital's perspective. METHODS Unit costs were collected from 30 oncological and hematological departments of 6 university and 24 general hospitals. Costs included direct labor and indirect labor, hotel and nutrition, overheads and capital. Ordinary least squares regression models were constructed to examine the degree of association between unit costs and hospital and hospital department characteristics. All costs were based on Euro 2007 cost data. RESULTS At university hospitals, the unit costs per inpatient day were determined at €633 in oncological and €680 in hematological departments. At general hospitals, the mean costs per inpatient day were €400. Unit costs for inpatient hospital days, outpatient visits. and daycare treatments equalled the relative ratio 100:21:44. Direct labor costs were the major cost driver and the type of hospital (university, yes/no) was a strong predictor of unit costs. CONCLUSIONS The present study provided unit costs for inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. The results may be used as Dutch reference unit prices in economic evaluations assessing oncological and hematological diseases.
Collapse
Affiliation(s)
- Siok Swan Tan
- Erasmus Universiteit Rotterdam, Institute for Medical Technology Assessment, Rotterdam, The Netherlands.
| | | | | | | | | |
Collapse
|
8
|
El-Zimaity MM, Hassan EA, Abd El-Wahab SE, Abd El-Ghaffar AA, Mahmoud NA, Elafifi AM, Moussa MM, El-Gohary GM, Hagras MM, Mowafy NM. Stem cell transplantation in hematological disorders. A developing country experience-impact of cost considerations. Saudi Med J 2008; 29:1484-1489. [PMID: 18946578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
OBJECTIVE To describe the experience in setting up a bone marrow transplant program at Ain Shams University, Cairo, Egypt. METHODS Sixteen patients were transplanted at Ain Shams University Bone Marrow Transplantation unit from March 2005 to January 2008. RESULTS Sixteen patients were transplanted with a median age of 25 years. Indications for transplantation were chronic myeloid leukemia, acute myeloid leukemia, aplastic anemia, acute lymphoblastic leukemia, and aggressive lymphoma. Seven donors and 6 patients were positive for cytomegalovirus immunoglobulin G (IgG) antibody (Ab) pretransplant. Only one patient was positive for toxoplasma IgG Ab and another had a high titre for toxoplasma IgM Ab pretransplant. Two donors and 2 recipients were positive for hepatitis B antibody markers; however, none were positive for hepatitis B virus DNA by polymerase chain reaction (PCR). None of the patients or donors were positive for hepatitis C virus via PCR pre-transplant. Acute graft versus host disease (GVHD) was seen in 3 patients, while chronic GVHD was seen in 5 patients. Primary cause of death was recurrence in 2 patients and graft failure in one patient. Thirteen are alive and disease free with a median follow-up of 20 months. CONCLUSION Although our unit is a relatively new unit, these results are comparable to those achieved in the Western world and cost a mean of US$250,000.
Collapse
Affiliation(s)
- Maha M El-Zimaity
- Department of Clinical Hematology and Bone Marrow Transplantation, Ain Shams University, Cairo, Egypt.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Heart, lung and blood diseases exert an enormous toll, accounting for almost half of the deaths in the USA each year. In addition to the morbidity and mortality resulting from these diseases, there is also a high economic burden, estimated at 560 billion US dollars for 2006. Nanotechnology offers a broad range of opportunities to improve diagnosis and therapy for cardiovascular, pulmonary and hematopoietic diseases, thereby decreasing these burdens. This review will focus on four areas of particular promise for the application of nanotechnology: imaging, diagnostics and biosensors, drug delivery and therapy, and tissue engineering and repair. The goal is to summarize the current state of science and technology in these areas and to look at future directions that the field is likely to move in to enhance the diagnosis and treatment of heart, lung and blood diseases.
Collapse
Affiliation(s)
- Denis B Buxton
- National Heart, Lung, & Blood Institute, Advanced Technologies & Surgery Branch, Division of Cardiovascular Diseases, Bethesda, MD 20892, USA.
| |
Collapse
|
10
|
Miyachi H, Asai S, Takemura Y. A cost-effectiveness evaluation of reticulocyte measurement in new outpatients with or without hematologic disorders. Clin Chem Lab Med 2006; 44:1035-8. [PMID: 16879074 DOI: 10.1515/cclm.2006.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Although reticulocyte counts provide very useful information, few studies have analyzed the cost-effectiveness of this testing. METHODS The yield and cost of reticulocyte count testing were analyzed in 719 new outpatients who visited the comprehensive medicine clinics and received both reticulocyte and complete blood count (CBC) testing. A "useful result" (UR) of the testing was defined as a finding that contributed to a change in a physician's diagnosis or decision-making between the pre- and post-test diagnosis. Patients' medical records were thoroughly reviewed for the assignment of URs. A simulation study was performed, blinding the reticulocyte data to the examiners, for the determination of URs generated by CBC alone. RESULTS CBC and reticulocyte testing generated a total of 838 URs in 719 patients, while the simulation study demonstrated 612 URs with CBC testing alone. When patients were grouped into 11 major disease categories according to a pre-test diagnosis, clinical effectiveness (UR/patient) varied from 1.69 (hematologic) to 0.13 (metabolic/endocrine patients), with a cost disparity from 206yen to 2784yen/UR. The cost-effectiveness (Deltacost/DeltaUR) of reticulocyte addition against CBC alone was 515yen per additional UR as a whole. Reticulocyte testing showed favorable cost-effectiveness in gastrointestinal ( 234yen) and hematologic patients ( 338yen/additional UR), while the test added few URs in metabolic/endocrine and neurologic patients, resulting in possibly unacceptable cost-effectiveness ( 3240yen and 2916yen/additional UR, respectively). CONCLUSIONS Wide disparity in its cost-effectiveness among patients apparently indicated that reticulocyte count testing should be performed for selected patient groups on the basis of its cost-effectiveness.
Collapse
Affiliation(s)
- Hayato Miyachi
- Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
| | | | | |
Collapse
|
11
|
Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH, Soiffer RJ. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002; 100:2697-702. [PMID: 12351374 DOI: 10.1182/blood-2002-03-0984] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
T-cell depletion (TCD) and immunosuppressive medications (ISTs) are 2 methods used for graft-versus-host disease (GVHD) prophylaxis in unrelated donor (URD) transplantation. However, comparisons of the clinical outcomes including quality of life and direct medical costs associated with each type of procedure have not been reported. We reviewed 48 TCD and 98 IST procedures performed from 1/1/97 to 12/31/99 at the Dana-Farber Cancer Institute, Boston, MA. With a median follow-up of 1.5 years for survivors, no differences were seen in relapse, acute GVHD, and overall survival between TCD and IST patients. Multivariable Cox modeling showed that age of 50 years or less (P =.002) and low-risk disease (P =.001) predicted survival, but method of GVHD prophylaxis (P =.6) and degree of human leukocyte antigen (HLA) matching (P =.8) did not. A subset of patients (53%) completed quality of life surveys prior to and at 6 and 12 months after transplantation; participation in the quality of life study was not associated with clinical characteristics and outcomes. No differences were seen in quality of life scores prior to transplantation, and changes over time were similar between groups. Costs ($113 000 vs $155 000, P <.0001) and total hospital days (34 vs 46, P =.0006) were significantly lower for patients undergoing TCD procedures. As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention.
Collapse
Affiliation(s)
- Stephanie J Lee
- Department of Adult Oncology and Department of Biostatistical Science, Dana-Farber Cancer Institute, and the Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
| | | | | | | | | | | | | |
Collapse
|
12
|
Vorob'ev AI. [From the editorial board]. TERAPEVT ARKH 2002; 73:5-6. [PMID: 11523409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
13
|
Koistinen P. [Thrombocyte and stem cell growth factors entering the clinics]. Duodecim 2002; 114:1171, 1173, 1175. [PMID: 11524762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
14
|
Chandy M, Srivastava A, Dennison D, Mathews V, George B. Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 2001; 27:785-90. [PMID: 11477434 DOI: 10.1038/sj.bmt.1702869] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2000] [Accepted: 01/12/2001] [Indexed: 11/09/2022]
Abstract
We describe our experience of setting up an allogeneic BMT program at the Christian Medical College Hospital, Vellore over a period of 13 years, from October 1986 to December 1999. Two hundred and twenty-one transplants were performed during this period in 214 patients, with seven patients undergoing second transplants. Indication for BMT were thalassemia major - 106 (48%), CML - 30, AML - 35, ALL - 10, SAA - 22, MDS - six and six for other miscellaneous disorders. The mean age of this patient cohort was 15.6 years (range 2-52). Graft-versus-host disease of grades III and IV was seen in 36 patients (17%) and this was the primary cause of death in 20 patients (9.2%). All patients and donors were CMV IgG positive. Sepsis was the primary cause of death in 16 patients (7.4%), 10 bacterial, four fungal and two viral. One hundred and ten of this series of patients are alive and disease free (50%) with a median follow-up of 24 months (range 2-116). These results are comparable to those achieved for patients with similar disease status in transplant units in the Western world and cost a mean of US$15 000.
Collapse
Affiliation(s)
- M Chandy
- Department of Hematology, Christian Medical College Hospital, Vellore, India
| | | | | | | | | |
Collapse
|
15
|
Paul C, Hast R. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use]. Lakartidningen 2000; 97:2862-6. [PMID: 10885223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- C Paul
- Hematologiska kliniken, Huddinge sjukhus, Stockholm
| | | |
Collapse
|
16
|
Affiliation(s)
- M F Murphy
- National Blood Service, John Radcliffe Hospital, Oxford, UK
| |
Collapse
|
17
|
Coetzee MJ, Badenhorst PN, le Loux EP, Doman MJ. Haematology outreach clinics in the Free State and northern Cape. S Afr Med J 1998; 88:702-6. [PMID: 9687847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
OBJECTIVE Evaluation of haematology outreach clinics in the Northern Cape and Free State. DESIGN Retrospective analysis of records from March 1994 to February 1996. SETTING Central South Africa is sparsely populated. Consultants from Bloemfontein held outpatient clinics in hospitals (with laboratories) in Bethlehem, Kimberley and Kroonstad. SUBJECTS 117 patients with suspected haematological disease. MAIN OUTCOME MEASURES Input measures (population, number of clinics and costs), process measures (patient numbers, patients per clinic, new consultations per clinic, patients' domicile, how they were referred, types of diagnoses and number of patients with non-haematological disorders) and output measures (attrition, changes in attendance and savings). MAIN RESULTS The 84 clinics that were held, with 636 consultations, did not cost the State anything. Only 6% of the 117 patients had no haematological problem. Sixty-eight per cent had chronic haematological neoplasms. In Kimberley most of the patients came from Kimberley Hospital, while most of the patients at the other clinics were referred via Bloemfontein. There was only a 10% attrition rate and only one-third of patients were referred to Bloemfontein. We saved paying patients an estimated R21,260 in transport costs, while saving the State R172,992 by seeing patients at secondary, instead of tertiary, hospitals. CONCLUSIONS It is cheaper to send a doctor to an outreach clinic than to refer patients to a central facility, provided there is enough work for a doctor at the clinic. It costs the State much less for patients to be seen at a secondary than a tertiary hospital. Positive spin-offs include academic stimulation of doctors and laboratories in the periphery, with more appropriate referrals to teaching hospitals. Weaknesses include poor availability of expensive drugs at the clinics and lack of standardised records. By commuting to outreach clinics, specialists can greatly reduce health expenditure and spread it from tertiary to lower levels. At the same time more patients have access to their services.
Collapse
Affiliation(s)
- M J Coetzee
- Department of Haematology, University of the Orange Free State, Bloemfontein
| | | | | | | |
Collapse
|
18
|
Fehr J. [Hematology: centuries: centuries of experiences/recent discoveries also cheaper]. Schweiz Med Wochenschr 1997; 127:2122-4. [PMID: 9487571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- J Fehr
- Leiter Abteilung Hämatologie, DIM, Universitätsspital, Zürich
| |
Collapse
|
19
|
Kessler KM. Cost analysis of procainamide-associated blood dyscrasias. Am J Cardiol 1995; 76:639-40. [PMID: 7677102 DOI: 10.1016/s0002-9149(99)80180-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
20
|
Abstract
Retrospective data were collected over a 1-year period from the medical records of patients admitted to a district general hospital, either with febrile neutropenia or who developed this complication whilst receiving inpatient chemotherapy. Costs were calculated for inpatient stay, drug treatment and diagnostic tests. The median total costs for 46 episodes of febrile neutropenia were 2068.35 pounds and the median total cost per day was 139.41 pounds. Inpatient bed-days accounted for 57.8% of total costs, followed by drug treatment at 25.8% and diagnostic tests at 16.4%. The costs of blood products were excluded since they are frequently administered irrespective of the neutropenia. This study serves as a useful pointer to the expenditure in measurable antibiotic costs and investigations in patients with malignant blood disorders who develop febrile neutropenia.
Collapse
Affiliation(s)
- B Leese
- Centre for Health Economics, University of York, England
| | | | | |
Collapse
|
21
|
Hast R, Hedenus M, Ljungman P, Stenke L, Westin J, Winqvist I. [Improved chances to cure hematologic diseases. The status of resources and organization of hematologic care]. Lakartidningen 1993; 90:2315-7. [PMID: 8316010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- R Hast
- Medicinska kliniken, Danderyds sjukhus
| | | | | | | | | | | |
Collapse
|
22
|
Richter J. [Need for thrombocytes among hematologic patients. Medical and economic aspects]. Lakartidningen 1993; 90:1390-3. [PMID: 8479264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
23
|
NIH Center grants--PHS. Final rule. Fed Regist 1985; 50:49692-4. [PMID: 10274733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
These final regulations govern the provision of financial assistance to National Research and Demonstration Centers for Heart, Blood Vessel, Lung and Blood Disease and Blood Resources, Multipurpose Arthritis Centers and Diabetes Research and Training Centers.
Collapse
|
24
|
Alberti R. [Mass screening for microcythemia]. Minerva Med 1983; 74:2909-14. [PMID: 6198606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|